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license (http://creativecommons.org/Abstract Pericardial disorders constitute a relatively common cause of heart disease.
Although acute pericarditis, especially the idiopathic forms that are the most prevalent, is
considered a benign disease overall, its short- and long-term complications, namely, recurrent
pericarditis, cardiac tamponade and constrictive pericarditis, constitute a matter of concern
in the medical community. In recent years, several clinical trials contributed to redefining
our traditional approach to pericardial diseases. In this review, we provide the most recent ev-
idence concerning diagnosis, treatment modalities and short- and long-term prognosis of the
most common pericardial disorders.
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4.0/).Pericardial diseases encompass a wide spectrum of clinical
conditions, ranging from benign and self-limiting forms to
life-threatening conditions.1,2 From a practical point of
view, the main pericardial syndromes include acute and
recurrent pericarditis either idiopathic or secondary with
or without concomitant pericardial effusion, chronicaros, MD FESC, First Cardiology D
el.: þ30 2132088099; fax: þ30 21
m (G. Lazaros).
f Hellenic Cardiological Society.
.11.024
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).constrictive pericarditis and isolated pericardial effusion
without evidence of ongoing pericardial inflammation.3
In recent years, several clinical trials focused on peri-
cardial diseases have enhanced our knowledge in this
context and contributed to the development of effective
and safe treatments, thus redefining several aspects of ourepartment, University of Athens, Hippokration Hospital, 114 Vas.
32088676.
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316 G. Lazaros et al.traditional view of pericardial diseases. The present review
aims to emphasize the most important advances in the field
of pericardiology and to provide helpful ‘tips and tricks’ for
an efficacious evidenced-based approach to the main
pericardial syndromes.
1. Acute pericarditis
The lack of well-established criteria for the diagnosis of
acute pericarditis was revealed to be an important con-
founding factor in the recent past, causing important
methodological divergences between investigations. Un-
fortunately, the absence of a pathognomonic marker, such
as troponins for myocardial necrosis, accounts for this
inconvenience. More recently, however, an expert
consensus on the diagnosis of acute pericarditis has
contributed to overcoming this inconvenience.4 Indeed,
acute pericarditis is considered when 2 out of the following
criteria are fulfilled: i) retrosternal chest pain sharing
several features with ischemic pain, which, however,
worsens in, for example, a supine position, deep inspira-
tion, cough, and swallowing and is relieved in the upright
position and by leaning forward; ii) pericardial friction rub,
which is pathognomonic for pericarditis but is unfortunately
present in one-third of patients;5 iii) typical electrocar-
diographic features with evolution in four stages in 60% of
cases (namely, diffuse concave ST segment elevation with
concomitant PR depression in the first stage, return to
baseline of the latter deviations and T wave flattening in
the second stage, diffuse T-wave inversion in the third
stage, and electrocardiographic normalization in the fourth
stage);2 and iv) new-appearing or worsening pericardial
effusion, which is observed in 60% of cases (80% mild, and
10% either moderate or large).6 In the abovementioned
main diagnostic criteria, 2 more variables have been added,
this time as supportive findings. The first is CRP elevation,
although apart from being found normal in w22% of cases
at presentation,7 has the additional limitation of low
overall specificity. The second is thickening and late gad-
olinium enhancement at the pericardial level in the cardiac
MRI (cMR), which is indicative of pericardial inflamma-
tion.5,8,9 It is stressed that both MRI and computed to-
mography are considered as a second line option in the
diagnostic work-up process of pericardial diseases and
should be performed when the rest of the findings are
inconclusive.2
The causes of acute pericarditis include infectious and
non-infectious forms and are summarized in Table 1.4 With
respect to the diagnostic approach, local epidemiologyTable 1 Most common causes of acute pericarditis.
Infectious (2/3 of cases)
Viral (most viral forms are labeled idiopathic since it is often
difficult and technically demanding to reveal an underlying
viral infection)
Bacterial (tuberculous in 4%e5% of cases)
Fungal or parasitic (extremely rare)should be always taken into account. For example, tuber-
culous pericarditis, which is a rare condition in the Western
word, is the most common cause of acute pericarditis
(w70e80%) in sub-Saharan Africa.4 Identification of the
causative infective agent in viral forms is not necessary in
every day practice since it does not add any therapeutic or
prognostic information.10 Although troponins do not seem
to have a prognostic impact on acute pericarditis, they
should be evaluated to exclude myopericarditis.4
Hospitalization in acute pericarditis should be restricted
only to high risk patients (high risk of non-viral, non-idio-
pathic etiology and complications during follow-up), who
should be investigated and treated accordingly. The major
criteria validated by multivariate analysis include large
pericardial effusion (>2 cm in diastole) with or without
tamponade, a fever >38C, subtle presentation over the
course of several days, and lack of responsiveness to the
non-steroidal anti-inflammatory treatment within 1 week
of therapy.4 Minor clinical poor prognostic criteria include
myopericarditis, immunodepression, traumatic pericarditis
and oral anticoagulant therapy. Patients with one or more
of the abovementioned criteria should be hospitalized and
subjected to an extensive etiologic search.4
Restriction of physical activity should be recommended
in all patients with acute pericarditis; however, this
recommendation applies only until complete clinical
remission along with CRP normalization. Competitive sports
are allowed at least 3 months after the index episode.11
Regarding medical treatment, the combination of
aspirin-NSAIDs with colchicine 0.5 mg twice daily (or 0.5 mg
once daily if <70kg) for 3 months is the mainstay
approach.2,11,12 Aspirin and ibuprofen are the medications
most frequently administered worldwide. Although they
are highly effective in controlling symptoms, neither of
them seem to affect the natural history and complication
rates of acute pericarditis.1 Particular attention should be
paid in using the highest tolerable doses of each medication
and assuring continuous anti-inflammatory coverage
throughout the day (e.g., each dose given every 8 hours for
ibuprofen and aspirin).11 The optimal treatment length and
the need for dose tapering have not been tested in clinical
trials, and similarly, no head to head comparisons between
anti-inflammatory agents have been performed. It is well-
established, however, that the full-dose regimen should
be offered at least until normalization of CRP values. Thus,
CRP monitoring is extremely helpful in individualizing the
duration of treatment. Although of doubtful benefit,
several experts recommend dose tapering of NSAIDs after
initial clinical remission and CRP normalization.2,11 DoseNon-infectious (1/3 of cases)
Autoimmune (including systemic autoimmune,
autoinflammatory diseases and pericardial injury
syndromes)
Neoplastic
Metabolic
Traumatic
Drug related (rare)
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and offer antiinflammatory protection throughout the
day.11 Details about the treatment schedule in acute peri-
carditis are depicted in Table 2.11
Colchicine should be administered in every case of acute
pericarditis (unless contraindicated) as it is the only
medication that has dramatically reduced (halved) the rate
of recurrences. To overcome potential problems with pa-
tients’ compliance and/or drug withdrawal, dose adjust-
ment should be performed according to age, body weight
and renal function (Table 2).13
Corticosteroids are a second-line treatment option in
patients with acute pericarditis. It seems that a dose be-
tween 0.2 and 0.5mg/kg/die of prednisone (or an equivalent
dose of an alternative agent) outmatches the dose of
1e1.5 mg/kg/die that is recommended in guidelines
regarding both safety and efficacy.2,4 The main problem
associated with steroid administration in pericarditis con-
cerns the higher rate of recurrences, probably caused by the
enhanced viral replication due to immunosuppression.
Despite this indisputable fact, steroid use should not be
‘demonized’ as it is a valuable treatment option in severalTable 2 Empiric treatment schedule in acute and recurrent pe
Drug Recommended attack dose Treat
dose
Aspirin 750e1000 mg tid (range 1.5e
4 g/daily)
Until
norma
Ibuprofen 600 mg tid (range 1.2e3.2 g/
daily)
Until
norma
Indomethacin 25e50 mg tid Until
norma
Colchicine Attack dose not necessary.
0.5 mg bid (0.5 mg/day if
<70 kg or intolerance, age
>70 years. Dose adjustment in
reduced creatinine clearance)
First a
recur
Prednisone 0.2e0.5 mg/kg/day (or
equivalent dose of another
corticosteroid)
Until
norma
Anakinra 1e2 mg/kg, up to 100 mg sc
daily
To be
admin
is usu
Azathiorpine 1.5e2.5 mg/kg/day Depen
patien
Intravenous
immunoglobulins
400e500 mg/kg/day 5 con
CRPZ C-reactive protein, bidZ twice a day, tidZ three times a dayconditions. To rephrasing a saying of Abraham Lincoln, ‘the
problemwith steroids relates not to the use of a bad thing but
to the abuse of a good thing.’ In fact, steroids should be used
when aspirin/NSAIDs are ineffective after at least 1 week of
treatment, provided that the highest tolerable dose has been
prescribed, in cases of true allergy of intolerance to the
latter medications, in secondary (specific) cases where ste-
roids constitute the recommended treatment (e.g., systemic
inflammatory diseases), in advanced kidney disease, in
pregnant women beyond the 20th week of gestation, and
probably in cases with intense inflammation and/or
concomitant pleuro-pericardial involvement (e.g., post-
pericardiotomy syndrome).1,4,5,11 A gradual tapering of
corticosteroids is essential, with each reductionmadeonly in
absence of symptoms and after CRP normalization, particu-
larly for dosages of prednisone lower than 10e15 mg daily.4
Last but not least, gastroprotection should be provided
to all patients under aspirin-NSAIDs treatment, and vitamin
D, calcium and diphosphonates should be administered
when >5e7.5 mg of prednisone are prescribed to pre-
menopausal women and men aged >50 years for 3
months.4,5,11,14ricarditis.
ment length with attack Tapering
symptoms and CRP
lization
Each week when CRP is
normalized (i.e., 1000 mg tid
for 1 week, 750 mg tid for 1
week then 500 mg tid for 1
week)
symptoms and CRP
lization
Each week when CRP is
normalized (i.e., 600e400
e600 mg/day for 1 week, 400
e400e600 mg/day for 1 week,
then 400 mg tid for 1 week)
symptoms and CRP
lization
Each week when CRP is
normalized (i.e. 50e25
e50 mg/day for 1 week, 25e25
e50 mg/day for 1 week, then
25 mg tid for 1 week)
ttack: 3 months,
rence: at least 6 months
May be required in recurrent
forms according to some
authorities
symptoms and CRP
lization
Tapering when CRP is
normalized. Slow tapering at
the threshold for the individual
patient for recurrences
established. Long-term
istration (6e12 months)
ally required.
Recommended by most
authorities
ds on the individual
t. Usually, >1 year
Not recommended
secutive days Repeated cycles may be
required according to the
clinical response
, scZ subcutaneously.
318 G. Lazaros et al.Prognosis of acute pericarditis is excellent in the idio-
pathic forms, with serious complications being uncommon
(tamponade 1.2% and permanent constriction w0.5% in a
60-month follow-up period).15 The rate of recurrence is
15e30% depending on the colchicine use, and the great
majority of recurrences are expected within 18e20
weeks.1,12,16 Myocardial involvement (myopericarditis)
does not seem to affect long-term prognosis, whereas cases
of perimyocarditis (prevalent myocardial involvement, with
affected contractility and regional wall motion abnormal-
ities) should probably be regarded and treated in the same
way with pure myocarditis treatment.4 The most severe
complication of acute pericarditis is cardiac tamponade.
Timely recognition and treatment of tamponade is of
paramount importance since hemodynamic collapse can
lead rapidly to death. Recently, the European Society of
cardiology proposed a scoring system that aims to affect
the decision regarding the timing of pericardial drainage.17
The abovementioned score-system takes into account
several parameters including etiology, clinical presenta-
tion, and imaging and offers information about the indica-
tion of immediate or urgent need for drainage (either
percutaneous or surgical), or about the possibility of
scheduling the procedure safely on an elective basis and
transferring patients to a specialized institution.2. Recurrent pericarditis
Recurrent pericarditis is the most problematic complication
of acute pericarditis due to its detrimental impact on pa-
tients’ quality of life. In the era of colchicine, the rate of
recurrence has been dramatically reduced to approxi-
mately 17%, at least in idiopathic forms.12,16 Patients with a
first recurrence have an even higher percentage of a second
one (up to 50%) and approximately half of all cases exhibit
1e2 recurrences (although individual cases with many re-
currences have been reported).1,2,16,18
The mechanisms involved in pericarditis recurrences
classically include infections (exacerbations of the initial
one or reinfections), an inadequate initial full dose regimen
or too rapid drug tapering, or autoimmunity, which is
believed to account for 2/3 of cases.16,19e21 A novel piece
of research, however, has recently added another possible
mechanism involved in relapse appearance, namely, auto-
inflammation.19,21 Autoinflammatory diseases include those
genetic disorders characterized by primary dysfunction of
the innate immune system. These diseases appear with
recurrent episodes of serosal inflammation, leukocytosis,
and familial occurrence. Examples are Familial Mediterra-
nean Fever and the tumor-necrosis factor receptor-1-
associated periodic syndrome (TRAPS), which in a rele-
vant investigation accounted for 6% of recurrent idiopathic
pericarditis cases.22 Autoinflammatory disorders should be
considered in cases of early onset of the disease, positive
family history for pericarditis, late relapses (>18e20
months), and most importantly, failure of colchicine ther-
apy and need for immunosuppression to control the
disease.22
It is reasonable for diagnostic work-up in recurrent cases
to be more extensive and include second option tests and
diagnostic pathways, in an effort to unveil secondary andpotentially treatable secondary conditions. It is empha-
sized that idiopathic recurrent pericarditis is not neces-
sarily a life-time diagnosis and patients should be
periodically reassessed for clinical and laboratory markers
of secondary forms. In a relevant investigation with long-
term follow up, a secondary form emerged in w10% of
cases, mainly a connective tissue disease.23
As already described, for acute pericarditis, the treat-
ment options for recurrent forms include aspirin-NSAIDs,
colchicine and corticosteroids, and the overall manage-
ment should be tailored in an individualized fashion.1,3,4,24
Although the dose regimens are largely the same in acute
and recurrent pericarditis, the treatment length should be
more extended (perhaps doubled) in the latter, at least
according to some experts.4,25 CRP serum levels should be
monitored in order to access treatment efficacy and
schedule dose tapering and treatment length.4 (Table 2).
Colchicine is the mainstay treatment in recurrent peri-
carditis. Its safety and effectiveness in this setting has been
tested in several clinical trials including CORE, CORP and
CORP-2.26e28 Colchicine was proved effective (and safe) in
the whole spectrum of recurrent pericarditis, such as first
recurrence (CORE-CORP)26,27 and multiple recurrences
(CORP-2).28 Thus, colchicine use has a class I indication in
recurrent pericarditis, where the administration of 0.5 mg
bid (or adjusted regimen where required) halves the per-
centage of first or subsequent recurrences.2 Steroids
administered at the lower effective dosages constitute a
valid treatment option in all clinical scenarios already
described for acute pericarditis. Dose tapering should be
very slow at the critical threshold for the individual patient
for recurrences.2 In case of symptom recurrence during
steroid tapering, administration of aspirin or NSAIDs is
recommended in an effort to avoid an increase of in the
steroid dose, which leads to vicious cycles.4
In recent years, the term refractory idiopathic recurrent
pericarditis (or colchicine-resistant steroid-dependent
pericarditis) has been introduced in clinical practice to
describe hard-to-control cases with multiple recurrences
that require high doses of corticosteroids (namely, predni-
sone >15 mg daily or equivalent) for long periods to be
controlled.4 True refractory pericarditis accounts for
approximately 5% of recurrent cases.5 Referral of these
difficult-to-treat patients to specialized centers for evalu-
ation and treatment is strongly encouraged. According to
the best available evidence, treatment options in true re-
fractory recurrent pericarditis include the following op-
tions. The first consists of combined triple therapy
including corticosteroids, colchicine and aspirin or NSAIDs.
Aspirin-NSAIDs should preferably be added when recurrence
appears, or earlier when the dose threshold of steroids for
relapses is being reached.4 In patients receiving steroids/
NSAIDs to control symptoms, the decision to withdraw
steroids or NSAIDs first should be considered on an indi-
vidual basis, taking into account the patient’s tolerance
and overall profile. Nevertheless, any drug dose tapering or
discontinuation should be preceded by CRP normalization.
Alternatives to the abovementioned treatments include
classic immunosuppressant (mainly azathioprine), ana-
kinra, and intravenous immunoglobulins. Because all the
above options are off-label and adverse effects are a
serious matter of concern, all potential candidates should
Untying the Gordian knot of pericardial diseases 319be informed of possible side effects in detail and an
informed consent is mandatory. Azathioprine is the most
widely used agent over time in this context. Data on its
efficacy are available from a retrospective study including
40 cases.29 The dose administered was 1.5e2.5 mg/kg/day
(mean 2.12 mg) and the mean time period on treatment
wasw14 months (Table 2). The medication turned out both
safe and effective in reducing the number of recurrences.
Most importantly, in a considerable proportion of patients
(w60%), it caused sustained remission of the disease after
discontinuation of steroids. It should be stressed that
azathioprine has a delayed onset of action (>1.5 months)
and thus it is not suitable for the treatment of the acute
attack.
Anakinra is another treatment option recently intro-
duced in the medical armamentarium for recurrent peri-
carditis. It is an interleukin-1 antagonist administered at a
daily dose of 100 mg in adults that is delivered through a
subcutaneous injection for at least 6e12 months.30e33 In a
recent systematic review of all published cases, anakinra
turned out to be a safe and highly effective steroid sparing
agent.32 The drug allowed immediate clinical remission
with CRP normalization within a few days. During the full-
dose regimen, no cases of symptom recurrence have been
reported. After drug discontinuation, however, recurrences
appear early (within few weeks), at a rate of w75%.
Gradual tapering according to preliminary observations
seems to lower the rate of recurrences.32
Finally, according to a recent systematic review, intra-
venous immunoglobulins administered at a daily dose of 400
to 500 mg/kg for 5 consecutive days constitute a well-
tolerated, rapidly acting, and effective steroid-sparing
option in refractory recurrent pericarditis.34
We wish to stress that the abovementioned off-label
alternatives to conventional treatment are not based on
solid evidence and treatment choices should depend on
local expertise and availability. Pericardiectomy today is
rarely required and should be regarded as the last resort in
refractory pericarditis cases presenting with recurrent
tamponade, and in patients unable to tolerate the afore-
mentioned conventional treatment. In centers of excel-
lence, the perioperative mortality and major morbidity and
are very low (0 and 3%, respectively).35
The prognosis of recurrent pericarditis is excellent in
idiopathic forms, while in secondary ones, the underlying
condition mainly affects the long-term outcome.4,36 In a
systematic review of all publications including 230 patients
with a follow-up of w60 months, the rate of tamponade
was 3.5% (occurring mostly during the initial attack),
whereas cases of constrictive pericarditis and left ventric-
ular dysfunction were never reported.37
Beyond efficacious treatment, the primary goal for
health physicians managing pericardial diseases should be
the prevention of recurrences, rather than their treatment.
In this context, the inappropriate use of medical therapies
may account for disease recurrence at least in a subset of
cases. For instance, the early (and unjustified) use of ste-
roids may facilitate viral replication and disease recur-
rence. Moreover, rapid tapering or discontinuation of anti-
inflammatory therapy before complete symptom remission
and CRP normalization, as well as colchicine non-use, are
associated with recurrent disease.4 Additional research isurgently required to identify those patients prone to re-
currences and clarify the mechanisms leading to disease
recurrence.383. Constrictive pericarditis
Constrictive pericarditis along with pericardial tamponade
and recurrent pericarditis constitute the most common
complications of pericarditis.15 The appearance of peri-
cardial constriction is rather rare in acute idiopathic peri-
carditis and exceptional as already mentioned in recurrent
pericarditis. In tuberculosis endemic areas, however,
constrictive pericarditis is a major health care problem
with high morbidity and mortality.4,15 Thus, awareness of
the local epidemiology is very important in tracking,
investigating and diagnosing the disease.
Concerning the diagnostic work-up in constrictive peri-
carditis, today, echocardiography with the application of
novel echocardiographic techniques (including tissue
Doppler imaging and speckle tracking), computed tomog-
raphy, and cardiac MRI (cMR) with gadolinium have
improved diagnostic accuracy and allowed the diagnosis of
the disease at earlier stages before myocardial involve-
ment, which negatively affects patient outcomes.8 In
particular, cMR with cine imaging highlights in an excellent
way the interventricular interdependence observed in
constriction pericarditis through the pathological motion
(bounce) of the interventricular septum. Most importantly,
with the use of modern imaging modalities, the use of
cardiac catheterization, which is classically considered the
gold-standard for the diagnosis of pericardial constriction,
may be omitted on occasion. In the Mayo Clinic group’s
recently published echocardiographic criteria for the diag-
nosis of constrictive pericarditis, cardiac catheterization
was not considered a prerequisite for the final diagnosis and
it has been performed only in 48% of patients before
operation.39 It should be emphasized that increased peri-
cardial thickness that has been traditionally considered an
essential finding to diagnose constrictive pericarditis is not
observed in 18% of surgically proven cases.40
Constrictive pericarditis has traditionally been consid-
ered a condition requiring surgical management, and total
pericardiectomy is the recommended treatment option.4,41
Patient candidates for surgical treatment are those needing
chronic diuretic therapy and exhibiting increasing jugular
venous pressure, evidence of hepatic impairment, and
reduced exercise tolerance.2,42 In contrast, surgical treat-
ment is not indicated in early asymptomatic constriction or
in advanced stages with myocardial fibrosis and severe
functional impairment (NYHA class IV). The operative
mortality in the latter cases is quite prohibitive (30e40%
compared with 6e19% in a lower NYHA class).2,42
In recent years, the term transient constriction has been
introduced in clinical practice by Sagrista-Sauleda et al. to
describe a transitory constriction physiology observed in 9%
of patients with acute effusive pericarditis during the res-
olution phase of the effusion.43 In the authors’ experience,
constriction in such cases regressed within a mean time of
2.7 months.
In a subsequent review published by the Mayo Clinic
group, the rate of transient constriction in 212 patients first
320 G. Lazaros et al.presenting with echocardiographic findings of constrictive
pericarditis was 17%.44 The average time elapsed between
initial diagnosis and resolution of the disorder in this
database was 8.3 weeks. Interestingly, no transitory forms
were observed in patients with constrictive pericarditis
following radiation therapy. Patients with reversible
constriction were treated with various medication regimens
(mainly NSAIDS and steroids), whereas spontaneous hae-
modynamics normalization was observed in 14% of cases.
To summarize, the important new concept that arose
from the above observations is that in hemodynamically
stable patients who present for the first time with features
suggesting constrictive pericarditis, a trial of anti-
inflammatory treatment (probably of 2e3 months duration)
may be offered before referral for total pericardiectomy.4
The role of imaging in predicting transient vs. perma-
nent forms of constriction is very important. Baseline late
gadolinium enhancement (LGE) pericardial thickness
>3 mm (sensitivity 86% and specificity 80%) and qualitative
LGE intensity (moderate or severe in 93% of transient forms
and 33% in permanent, pZ 0.002) emerged as the most
powerful parameters for the prediction of transient
forms.45 In addition, higher baseline CRP values were able
to differentiate transient and permanent forms (59 52
versus 12 14 mg/L, pZ 0.04).454. Chronic idiopathic pericardial effusion
This section addresses the incidental finding of pericardial
effusion in either symptomatic or asymptomatic patients in
the absence of clinical and laboratory findings (mainly CRP
elevation) suggesting acute pericarditis.
It is implied than even in the absence of evidence of a
specific cause, a detailed medical history and clinical ex-
amination as well as a group of blood tests possiblyFigure 1 Recommended triage of patients with pericardial effus
with CRP elevation, which should be treated according to the reco
the cycles include pericardial effusion cases without CRP elevation
(small, moderate and large) of pericardial effusion.including screening for common causes of pericardial
effusion (such as thyroid and kidney function tests and
screening for connective tissue diseases) should be under-
taken in an effort to establish a secondary condition,
especially for moderate and large effusions.4
Pericardial effusion is defined as chronic if it persists for
longer than a 3-month time period.2,4 In the presence of
chronic pericardial effusion, it is reasonable for the treat-
ing physician to express concerns with respect to the evo-
lution of the disorder towards cardiac tamponade and
hemodynamic collapse. In this context, the amount of
pericardial effusion may have a predictive role. Indeed,
small pericardial effusions have been traditionally regarded
as a benign condition, and as such, not requiring specific
treatment and close follow-up.4 Concerns about the latter
approach were raised by a recent publication where even
small sized pericardial effusions (<1 cm in diastole) were
found to be independently associated with mortality, even
after adjustment for several possible confounders.46
Although the abovementioned (and unexpected results)
need confirmation in future trials, the latter study made a
substantial contribution in the assessment of the progres-
sion (or regression) of small-sized pericardial effusions.
During a mean follow up of 2.3 1.9 years, 60% of effusions
were resolved, 28% remained unchanged and 5% increased,
although no case of tamponade was recorded.46
In cases of moderate pericardial effusion (sized>1 cm
and <2 cm in diastole) the index of suspicion of an under-
lying condition should be high since approximately 60% of
cases with moderate to large effusions are associated with
secondary conditions.4 Pericardiocentesis, if technically
feasible, should be deserved to symptomatic patients or
when a neoplastic or bacterial etiology (including tuber-
culosis) are suspected.47
In the presence of a large pericardial effusion with he-
modynamic impairment, pericardicentesis is a mandatoryion. The intersecting part of the 3 cycles corresponds to cases
mmendations provided for acute pericarditis. The free parts of
. In the latter cases, the management depends on the degree
Untying the Gordian knot of pericardial diseases 321procedure to prevent circulatory collapse.4 Notably, when
cardiac tamponade occurs in the absence of inflammatory
markers, the possibility of neoplastic disease is quite high.4
In the absence of cardiac tamponade, the indications of
pericardiocentesis are the same as those above reported
for moderate effusions. According to some authorities, any
large chronic idiopathic pericardial effusion, particularly in
the presence of right chamber collapse, should be treated
with pericardiocentesis as approximately 1/3 of cases may
progress to cardiac tamponade in the long term, either
unexpectedly or in such contexts as acute pericarditis and
chest trauma.4,48
Finally, in the absence of ongoing inflammation (i.e.,
elevated CRP) conservative treatment of chronic idiopathic
effusions of any size with medical therapy (including
aspirin-NSAIDs, colchicine and/or steroids) is not effec-
tive.4 In Figure 1, the recommended approach for patients
with chronic pericardial effusion is provided with respect to
the presence or absence of inflammation and to the effu-
sion site.
5. Conclusions
In recent years, several trials have changed our traditional
clinical practice in the field of pericardial diseases con-
cerning diagnostic work-up and medical therapy. It is
important for physicians to become familiar with the cur-
rent trends to treat their patients successfully according to
the best available evidence. Although several pieces of the
puzzle of pericardial disorders are still missing, ongoing
clinical and basic research are expected to provide the rest
of information needed to untie the Gordian knot of peri-
cardial diseases.
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